Menin/Histone-lysine N-methyltransferase MLL · PROTEIN-PROTEIN INTERACTION · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Menin/Histone-lysine N-methyltransferase MLL shows clinical signal disease relevance led by acute myeloid leukemia. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt O00255. Start with acute myeloid leukemia, then reuse UniProt O00255 as the stable protein anchor across project notes and exports.
Start with acute myeloid leukemia, then reuse UniProt O00255 as the stable protein anchor across project notes and exports.
Menin/Histone-lysine N-methyltransferase MLL shows clinical signal disease relevance led by acute myeloid leukemia. 1 linked drug remains visible in the same block.
Start review with acute myeloid leukemia because it currently carries clinical signal support. Linked drugs include REVUMENIB SESQUIFUMARATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyMenin
Review this target as Menin/Histone-lysine N-methyltransferase MLL, mapped to UniProt O00255. ChEMBL maps the protein component as Menin. Sequence length is 610 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Menin/Histone-lysine N-methyltransferase MLL as ChEMBL target CHEMBL2093861, mapped to UniProt O00255. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Menin/Histone-lysine N-methyltransferase MLL is the right protein anchor across sources, using UniProt O00255 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why acute myeloid leukemia is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Menin/Histone-lysine N-methyltransferase MLL |
| Target Type | PROTEIN-PROTEIN INTERACTION |
| Organism | Homo sapiens |
| UniProt | O00255 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Menin |
| UniProt Accession | O00255 |
| Component Type | Protein |
| Sequence Length | 610 aa |
Menin
Review this target as Menin/Histone-lysine N-methyltransferase MLL, mapped to UniProt O00255. ChEMBL maps the protein component as Menin. Sequence length is 610 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Menin/Histone-lysine N-methyltransferase MLL shows clinical signal disease relevance led by acute myeloid leukemia.
Start review with acute myeloid leukemia because it currently carries clinical signal support. Linked drugs include REVUMENIB SESQUIFUMARATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL5272148 | 9.3 | IC50 | 0.5 | Preclinical |
| CHEMBL5414266 | 9.3 | IC50 | 0.5 | Preclinical |
| CHEMBL4216333 | 9.08 | IC50 | 0.83 | Preclinical |
| CHEMBL5282452 | 9.0 | IC50 | 1.0 | Preclinical |
| CHEMBL4788214 | 8.63 | IC50 | 2.35 | Preclinical |
| CHEMBL4435830 | 8.52 | IC50 | 3.0 | Preclinical |
| CHEMBL6017372 | 8.39 | IC50 | 4.1 | Preclinical |
| CHEMBL4777030 | 8.34 | IC50 | 4.6 | Preclinical |
| CHEMBL5277316 | 8.33 | IC50 | 4.7 | Preclinical |
| CHEMBL6067935 | 8.28 | IC50 | 5.3 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| protein format | 24 | 193 | 6.7 |
| cell-based format | 6 | 0 | — |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 6 | 0 | — |